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Abstract
Background: There are no well-established predictors of recurrent ischemic coronary events after 
an acute coronary syndrome (ACS). Higher levels of homocysteine have been reported to be associated 
with an increased atherosclerotic burden. The primary endpoint was to assess the relationship between 
homocysteine at discharge and very long-term recurrent myocardial infarction (MI).
Methods: 1306 consecutive patients with ACS were evaluated (862 with non-ST-segment elevation 
ACS [NSTEACS] and 444 with ST-segment elevation myocardial infarction [STEMI]) discharged 
from October 2000 to June 2003 in a single teaching-center. The relationship between homocysteine at 
discharge and recurrent MI was evaluated through bivariate negative binomial regression accounting 
for mortality as a competitive event.
Results: The mean age was 66.8 ± 12.4 years, 69.1% were men, and 32.2% showed prior diabetes 
mellitus. Most of the patients were admitted for an NSTEACS (66.0%). The median (interquartile 
range) GRACE risk score, Charlson comorbidity index, and homocysteine were 144 (122–175) points, 
1 (1–2) points, and 11.9 (9.3–15.6) µmol/L, respectively. In-hospital revascularization was performed 
in 26.3% of patients. At a median follow-up of 9.7 (4.5–15.1) years, 709 (54.3%) deaths were registered 
and 779 recurrent MI in 478 (36.6%) patients. The rates of recurrent MI were higher in patients in 
the upper homocysteine quartiles (p < 0.001). After a multivariate adjustment, homocysteine along its 
continuum remained almost linearly associated with a higher risk of recurrent MI (p = 0.001) and 
all-cause mortality (p < 0.001). 
Conclusions: In patients with ACS, higher homocysteine levels identified those at a higher risk of 
recurrent MI at very long-term follow-up.  (Cardiol J 2021; 28, 4: 598–606)
Key words: homocysteine, acute coronary syndrome, recurrent myocardial infarction, 
coronary artery disease, risk factors
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Introduction
Ischemic heart disease (IHD) remains the 
leading cause of death worldwide, despite advances 
in prevention, diagnosis, and treatment [1]. Identi-
fying those at a higher risk of new cardiovascular 
ischemic events is essential for tailoring monitor-
ing and therapeutics. Unfortunately, there are not 
well established biomarkers for predicting the risk 
of long-term recurrent myocardial infarction (MI) 
after an episode of acute coronary syndrome (ACS). 
Mild elevations of homocysteine, a toxic 
sulfhydryl-containing amino acid formed during 
the demethylation of methionine, have been as-
sociated with an increased incidence of cardio-
vascular, cerebrovascular, or peripheral vascular 
diseases [2–5]. Although the exact biological 
pro-atherogenic effect of homocysteine remains 
to be determined, multiple mechanisms have been 
proposed. Among them, endothelial dysfunction, 
direct effects on platelets, smooth muscle pro-
liferation, oxidative modification of low-density 
lipoproteins, endothelial-leukocyte interactions, 
and inhibition of fibrinolysis have been described 
in vitro and in vivo studies [6–9]. However, some 
studies failed to confirm the relationship between 
higher homocysteine and adverse clinical events 
[10, 11]. Most of these studies were performed in 
a healthy population, with a median follow-up of up 
to 5 years, and evaluated time to a first event [3, 8, 9]. 
According to available research, there is no data in 
the literature endorsing the role of homocysteine 
for predicting long-term recurrent MI in patients 
with established IHD.
In this work, the aim was to evaluate whether 
homocysteine was associated with total long-term 




A total of 1606 consecutive patients were 
hospitalized in a single-teaching center with 
a diagnosis of ACS from October 2000 to August 
2003. None of these patients were transferred 
from other hospitals due to unsatisfactory clinical 
progress. Patients who died (n = 119) during the 
index admission were excluded from this analysis. 
Additionally, 181 patients without homocysteine 
assessment were excluded. Finally, 1306 patients 
comprised the final population for this analysis (862 
with non-ST-segment elevation ACS [NSTEACS] 
and 444 with ST-segment elevation MI [STEMI]) 
(see flow chart in Suppl. Fig. 1). The baseline 
characteristics between those with and without 
homocysteine assessment are shown in Supple-
mentary Table 1. ACS definition and treatment 
were based on current guidelines operating at the 
time of patient inclusion [12–14]. The Charlson 
comorbidity index [15] and the Global Registry of 
Acute Coronary Events (GRACE) score [16] were 
determined in all patients. 
For STEMI patients, fibrinolysis was the main 
reperfusion strategy at the time of enrolment. It 
was indicated in those presenting with ST-segment 
elevation (greater than 0.1 mV in two or more con-
tiguous leads) or new left bundle branch block and 
clinical history suggesting acute MI, and time to 
therapy of 12 hours or less. Rescue percutaneous 
coronary intervention was considered when the 
pharmacological reperfusion strategy failed [13, 
14]. In patients with NSTEACS, an initial non-
invasive strategy was applied. Cardiac catheteriza-
tion during the index hospitalization was indicated 
in patients with persistent or recurrent episodes of 
symptomatic ischemia with or without associated 
electrocardiogram changes, and in those presenting 
shock, severe pulmonary congestion, or continu-
ing hypotension [13, 14]. The treatment strategy 
followed was established by current national and 
international guides operating at the time of the 
study [13, 14].
Written informed consent was obtained from 
each patient included in the study. The study pro-
tocol conforms to the ethical guidelines of the 1975 
Declaration of Helsinki. The study protocol has 
been priorly approved by the Institution’s ethics 
committee on research on humans.
Blood samples
Plasma total homocysteine at discharge, which 
includes the sum of protein-bound and free homo-
cysteine, was measured by immunoassay of po-
larization of fluorescence (Axsym system, Abbott). 
The coefficients of variation within and between 
days for the analysis were ≤ 5%.
Outcome definition and follow-up
Recurrent spontaneous MI was selected as 
the primary endpoint, whereas all-cause mortality 
was considered as a secondary endpoint. Patient 
clinical status and endpoint ascertainment were 
routinely evaluated by trained cardiologists during 
ambulatory clinic visits or through a review of the 
hospital or outpatient national electronic medical 
records. Only spontaneous MI was selected as an 
endpoint. Spontaneous MI was defined as an eleva-
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tion of myocardial markers (troponin I or creatine 
kinase-MB mass) associated with chest pain or 
compatible symptoms or ST-segment deviation 
[12]. Personnel in charge of events adjudication 
were blinded to the clinical data and exposures.
Statistical analysis
Continuous variables were expressed as mean 
± standard deviation (SD) or median (interquartile 
range [IQR]) when appropriate. Differences among 
homocysteine quartiles were tested with the 
ANOVA or Kruskal-Wallis rank test, respectively. 
Discrete variables were presented as percentages 
and compared with the c2 test. 
Time to death and first MI (adjusting for death 
as a competing event) across quartiles of homo-
cysteine were plotted with the Kaplan-Meier and 
cumulative incidence function plots. Differences 
among the quartiles were tested with the log-rank 
test and Gray’s test, respectively. The primary 
endpoint (recurrent MI) was evaluated by deter-
mining the incidence rate ratio (IRR), which is 
a risk estimate used for this type of method. To 
that end, a negative binomial regression was used 
to assess the association between homocysteine 
and the number of total recurrent MI during the 
entire follow-up. Because an increase of MI is 
most likely associated with an increased risk of 
subsequent death, it has been suggested that 
any analysis of recurrent admissions should also 
account for death as a competitive and terminal 
event. Thus, coefficients from this method were 
estimated by accounting for the positive correla-
tion among the recurrent outcome and death as 
a terminal event, by linking the two simultaneous 
equations (rehospitalization count and death) with 
shared frailty [17]. Thus, within the same model, 
we obtain estimates of risk for both endpoints. 
Covariate selection was performed based on pre-
vious medical knowledge. The multivariable frac-
tional polynomial method was used to determine 
the appropriate functional form of continuous 
covariates [18]. The covariates included in the 
final predictive model for both endpoints were: 
gender, type of ACS (NSTEACS vs. STEMI), 
GRACE risk score, Charlson comorbidity index, 
and revascularization during the index hospital-
ization. 
A two-sided p-value of < 0.05 was set as the 
threshold for statistical significance. All analyses 
were performed with Stata 15.1 (Stata Statistical 
Software, Release 15 [2017]; StataCorp LP, College 
Station, TX, USA).
Results
The mean age of the patients was 66.8 ± 12.4 
years. Most of the patients were admitted for an 
NSTEACS (66.0%) and showed troponin elevation 
(69.5%). The proportion of males was 69.1%, 32.2% 
showed prior diabetes mellitus, 19.4% exhibited 
Killip class > I and 26.3% were revascularized 
during the index hospitalization. The median (IQR) 
GRACE risk score, Charlson comorbidity index, and 
homocysteine were 144 (122–175) points, 1 (1–2) 
points, and 11.9 (9.3–15.6) µmol/L, respectively.
Baseline characteristics among  
homocysteine quartiles
Baseline characteristics among homocysteine 
quartiles are presented in Table 1. Patients in the 
upper quartiles of homocysteine were older, more 
frequently males, and more often showed a history 
of hypertension, IHD, and Killip class > I during 
the index hospitalization. Also, they exhibited 
a higher GRACE score and the Charlson index. 
Homocysteine and risk  
of long-term recurrent MI 
At a median follow-up of 9.7 (4.5–15.1) years, 
709 (54.3%) deaths were registered and 779 re-
current MI in 478 (36.6%) patients (Fig. 1). The 
number of recurrent MIs per patient were 1, 2, 3 
and > 3 in 299 (22.9%), 112 (8.6%), 37 (2.8%), and 
32 (2.3%) patients, respectively. Patients in the 
upper quartile of homocysteine showed the high-
est cumulative incidence rates of a first MI during 
the entire follow-up (Fig. 2). Similarly, the rates of 
total MI were also higher in patients in the upper 
quartile (per 100-person-year): 4.1, 3.6, 3.8, and 7.3 
for Q1, Q2, Q3, and Q4, respectively p < 0.001). 
After a multivariate adjustment, including estab-
lished prognosticators and accounting for death as 
a terminal event, homocysteine along its continuum 
remained almost linearly associated with a higher 
risk of recurrent MI (p = 0.001), as is presented 
in Figure 3. When analyzed as quartiles, compared 
to those in the lower quartile, only patients in the 
upper quartile showed a significantly increased 
risk of recurrent MI (IRR = 1.42, 95% confidence 
interval [CI] 1.11–1.81, p = 0.005). 
Subgroup analyses revealed a non-differential 
effect across most representative subgroups such 
as age (≤ 65 vs. > 65 years), gender, history of 
diabetes, prior IHD, type of ACS (NSTEACS vs. 
STEMI), and Charlson comorbidity index (above 
vs. below median), as depicted in Supplementary 
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Figures 2, 3a and 3b. A significant differential 
association was found for the GRACE risk score 
(above vs. below median: p-value for interaction: 
0.003). This interaction revealed the magnitude of 
the association between homocysteine and the risk 
of recurrent MI was greater in those with GRACE 
risk scores below the median (Suppl. Fig. 3c).
A sensitivity analysis, forcing treatments 
at discharge (antiplatelets [dual treatment with 
acetylsalicylic acid plus clopidogrel], renin–angio-
tensin–aldosterone inhibitors, beta-blockers, and 
statins) and hemoglobin (as a potential confounder) 
as covariates into the multivariate analysis, showed 
that homocysteine remained positively associated 
Table 1. Baseline characteristics among homocysteine quartiles.


















Demographics and medical history
Age [years] 62.1 ± 12.7 65.5 ± 11.0 66.8 ± 12.2 73.0 ± 11.0 < 0.001
Sex (male) 203 (62.3%) 230 (70.3%) 242 (74.0%) 228 (69.9%) 0.020
Hypertension 176 (54.0%) 206 (63.0%) 197 (60.2%) 225 (69.0%) < 0.001
Diabetes 116 (35.6%) 106 (32.4%) 101 (30.9%) 97 (29.7%) 0.100
Dyslipidemia 152 (46.6%) 139 (42.5%) 143 (43.7%) 122 (37.4%) 0.031
Smoker 121 (37.1%) 104 (31.8%) 111 (33.9%) 72 (20.1%) < 0.001
Prior smoker 70 (21.5%) 85 (26.0%) 99 (30.3%) 101 (31.0%) 0.003
Family history of IHD 45 (13.8%) 30 (9.2%) 24 (7.3%) 21 (6.4%) 0.001
Prior IHD 105 (32.2%) 112 (34.2%) 124 (37.9%) 157 (48.2%) < 0.001
Prior MI 56 (17.2%) 69 (21.1%) 69 (21.1%) 91 (27.9%) 0.002
Previous PCI 21 (6.4%) 18 (5.5%) 19 (5.8%) 14 (4.3%) 0.677
Previous CABG 11 (3.4%) 18 (5.5%) 10 (3.1%) 18 (5.5%) 0.431












Killip class > I 52 (15.9%) 46 (14.1%) 56 (17.1%) 99 (30.4%) < 0.001
GRACE score [points] 136 (110–165) 139 (118–170) 144 (124–173) 164 (136–196) < 0.001
Vital signs on admission
Heart rate [bpm] 85 ± 19 83 ± 19 84 ± 17 87 ± 22 0.073
SBP [mmHg] 145 ± 26 144 ± 24 147 ± 24 145 ± 26 0.542
Electrocardiogram and echocardiography
ST segment deviation 175 (53.7%) 167 (51.1%) 173 (52.9%) 150 (46.0%) 0.088
LVEF [%]b 60 ± 13 59 ± 12 58 ± 13 56 ± 14 0.002
Laboratory
Creatinine [mg/dL] 0.97 ± 0.49 1.05 ± 0.40 1.16 ± 0.85 1.62 ± 1.23 < 0.001
Total cholesterol [mg/dL]c 194 ± 49 194 ± 38 192 ± 44 192 ± 41 0.626
Troponin I elevation (> 1 ng/mL)d 215 (67.6%) 216 (67.5%) 220 (69.2%) 236 (75.5%) 0.092
Revascularization during admission
Coronary angiography 184 (56.4%) 162 (49.5%) 168 (51.4%) 121 (37.1%) < 0.001
Revascularization 105 (32.2%) 91 (27.8%) 87 (26.6%) 60 (18.4%) < 0.001
Continuous variables are expressed as mean (standard deviation) unless otherwise specified. aValues are expressed as median (interquartile 
range); bData available in 976 (74.7%) patients; cData available in 1298 (99.4%) patients; dData available in 1277 (97.8%) patients; ACS — acute 
coronary syndrome; CABG — coronary artery by-pass graft; GRACE — Global Registry of Acute Coronary Events; IHD — ischemic heart dis-
ease; LVEF — left ventricle ejection fraction; MI — myocardial infarction; NSTEACS — non-ST-segment elevation acute coronary syndrome; 
PCI — percutaneous coronary intervention; SBP — systolic blood pressure; STEMI — ST-segment elevation acute myocardial infarction
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Figure 2. Time to a first myocardial infarction among homocysteine quartiles. 
Figure 1. Graphical abstract. 
with the risk of MI (p = 0.002). Indeed, under this 
multivariate scenario, patients in the upper vs. 
lowest quartile displayed a significant excess of 
risk (IRR = 1.41, 95% CI 1.10–1.80, p = 0.006). 
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Homocysteine and risk  
of long-term mortality  
During the follow-up, the incidence of death 
(per 100-person-year) significantly increased 
across homocysteine quartiles (3.7, 4.9, 5.7, 
and 10.7 for Q1, Q2, Q3, and Q4, respectively; 
p < 0.001). The Kaplan-Meier curves revealed 
a stepwise and sustained separation of the curves 
through the entire follow-up, especially for patients 
belonging to the upper quartile (Fig. 4A). Multi-
variate analysis confirmed that higher homocyst-
eine during index admission was associated with 
a higher risk of death (p < 0.001). This adjusted 
association also revealed an almost linear gradient 
of risk (Fig. 4B). When compared to patients in the 
lower quartile, adjusted-risk estimates showed 
a significative and stepwise increase of risk for 
Q2 (1.25, 95% CI 0.95–1.63, p = 0.107), Q3 (1.41, 
95% CI 1.08–1.84, p = 0.012), and Q4 (2.00, 95% 
CI 1.53–2.61, p < 0.001).
Discussion
This work evaluated the relationship between 
homocysteine and recurrent MI and mortality at 
very long-term follow-up in a historical cohort of 
consecutive non-selected patients with an ACS. 
The main finding herein, is that those patients 
with higher homocysteine values, assessed during 
hospitalization for an ACS, showed a higher risk of 
recurrent MI and mortality. Both associations were 
independent of traditional and relevant prognosti-
cators and potential confounders. These findings 
support the role of homocysteine in the pathogen-
esis of new acute coronary events in patients with 
coronary artery disease (CAD). 
Homocysteine and atherosclerosis
Homocysteine, a sulfur-containing amino acid, 
is an intermediate product formed as a result of the 
catabolism of methionine. It is known that severe 
hyperhomocysteinemia (>100 µmol/L) in patients 
with homozygous homocystinuria is associated 
with premature atherosclerosis [19]. Although 
this is a very rare pathology, minor elevated levels 
(15–30 µmol/L) have been described in up to 7% 
of the population [20].
The suggested mechanisms involved in homo-
cysteine-induced atherosclerosis include: a) endothe-
lial injury, which appears to be mediated by oxidative 
stress [21]; b) smooth muscle proliferation [22]; 
c) oxidative modification of low-density lipoproteins 
[6, 23, 24]; d) endothelial-leukocyte interactions [25]; 
e) reduced fibrinolytic activity [9, 26], and f) direct ef-
fects on platelets [27]. However, the specific weight of 
each of these mechanisms remains elusive, especially 
because many observations have been obtained from 
in vitro studies with homocysteine concentrations 
much higher than found in humans [8].
Homocysteine and prognosis in CAD
Several epidemiological studies have de-
scribed a high prevalence of elevated plasma levels 






























Figure 3. Homocysteine and baseline hazard of recurrent reinfarction; IRR — incidence rate ratio.
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peripheral artery disease, and venous thrombosis 
[2–5]. Prospective studies correlated serum homo-
cysteine levels to long-term outcomes in patients 
with STEMI [28], NSTACS [3], and without pre-
vious CAD [29]. In a meta-analysis, Boushey et 
al. [30] estimated that a 5-mmol/L homocysteine 
increment elevates CAD risk by as much as choles-
terol increases of 0.5 mmol/L. However, other au-
thors failed to confirm this association [10, 11]. For 
example, Ubbink et al. [11] showed no significant 
increase in CAD in those with higher homocysteine 
values in 2290 men in the Caerphilly cohort during 
a 5-year follow-up. Also, some randomized clinical 
trials, performed in subject with and without CAD, 
have failed to demonstrate any benefit in terms of 
reducing major cardiovascular events by lowering 
the homocysteine levels with diet supplementation 
with folic acid and B vitamins [31–33].
More recently, a higher risk of short-term 
mortality and nonfatal ischemic events has been 
reported in patients with NSTEACS [34] and STEMI 
[35]. In these studies, the risk of new recurrent coro-
Figure 4. Homocysteine and all-cause mortality; A. Time to all-cause mortality among homocysteine quartiles; 
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nary ischemic events at long-term follow-up was not 
addressed. Thus, this is the first study showing that 
higher levels of homocysteine are related to a higher 
risk of new coronary ischemic events.
Clinical implications
Reinfarction risk prediction in patients with 
established CAD is still an unmet need. The utility 
of homocysteine measurement after an index MI 
is not well-established. According to the present 
findings, higher levels of homocysteine may iden-
tify a subset of patients at a higher risk of new 
coronary ischemic events. These patients may 
probably benefit from a closer follow-up and more 
aggressive treatment. Further studies are neces-
sary to confirm the present findings in cohorts 
with more contemporary treatments, elucidate the 
mechanisms behind these findings, and re-evaluate 
the long-term effects of therapies for reducing 
homocysteine in patients with prior ACS.
Strengths and limitations
The main strength of the present study is 
the very-long follow-up, which allowed recording 
a large number of repeated new ischemic coronary 
events. Some important limitations need to be ad-
dressed: a) this is an observational single-center 
study, which may influence the applicability of these 
results to other populations; b) the generalization of 
our findings to the current era is limited by the fact 
that revascularization strategies and medical treat-
ment have substantially changed. In addition, given 
the low proportion of patients that received coronary 
artery bypass during the index admission, the po-
tential differential effect of type of revascularization 
along the continuum of homocysteine could not be 
evaluated; c) we did not assess the revascularization 
procedures nor medical treatment changes during 
the post-discharge follow-up, which may operate 
as important confounders; d) finally, in this study 
the longitudinal trajectory of homocysteine was not 
measured, precluding to infer how its trajectory may 
be associated with the risk of recurrent MI. Neverthe-
less, it has been reported that the occurrence of an 
MI does not change homocysteine plasma levels [36].
Conclusions
In patients with ACS, higher homocysteine 
levels identified those at a higher risk of recurrent 
MI very long-term follow-up. The present study 
results provide new evidence about the utility of 
homocysteine as a potential risk predictor of new 
coronary ischemic events. Further contemporary 
studies are warranted to re-evaluate the applicabil-
ity of the present findings to more contemporary 
cohorts and the role of homocysteine as a thera-
peutic target in this scenario.
Funding
This work was supported in part by grants 
from CIBER CV (grant number 16/11/00420) 
and Instituto de Salud Carlos III-FEDER (grant 
numbers PIE15/00013 and PI17/01836), Madrid, 
Spain. The authors have no other funding, financial 
relationships, or conflicts of interest to disclose 
relative to this work. 
The funding sources were not involved in the 
study design, collection, analysis and interpreta-
tion of data in the writing of the report, and in the 
decision to submit the article for publication.
Conflict of interest: None declared
References
1. Benjamin EJ, Muntner P, Alonso A, et al. American Heart Asso-
ciation Council on E, Prevention Statistics C, Stroke Statistics S. 
Heart Disease and Stroke Statistics-2019 Update: A Report 
From the American Heart Association. Circulation. 2019; 139: 
e56–e528.
2. Selhub J. The many facets of hyperhomocysteinemia: stud-
ies from the Framingham cohorts. J Nutr. 2006; 136(6 Suppl): 
1726S–1730S, doi: 10.1093/jn/136.6.1726S, indexed in Pubmed: 
16702347.
3. Fácila L, Nuñez JE, G VB, et al. Early determination of homo-
cysteine levels in acute coronary syndromes, is it an independ-
ent prognostic factor? Int J Cardiol. 2005; 100(2): 275–279, doi: 
10.1016/j.ijcard.2004.09.001, indexed in Pubmed: 15823635.
4. Bostom AG, Rosenberg IH, Silbershatz H, et al. Nonfasting 
plasma total homocysteine levels and stroke incidence in elderly 
persons: the Framingham Study. Ann Intern Med. 1999; 131(5): 
352–355, doi: 10.7326/0003-4819-131-5-199909070-00006, in-
dexed in Pubmed: 10475888.
5. Anderson JL, Muhlestein JB, Horne BD, et al. Plasma homocyst-
eine predicts mortality independently of traditional risk factors 
and C-reactive protein in patients with angiographically defined 
coronary artery disease. Circulation. 2000; 102(11): 1227–1232, 
doi: 10.1161/01.cir.102.11.1227, indexed in Pubmed: 10982535.
6. Holvoet P, Collen D. Oxidized lipoproteins in atherosclerosis 
and thrombosis. FASEB J. 1994; 8(15): 1279–1284, doi: 10.1096/
fasebj.8.15.8001740, indexed in Pubmed: 8001740.
7. McCully KS. Macromolecular basis for homocystein-induced 
changes in proteoglycan structure in growth and arteriosclerosis. 
Am J Pathol. 1972; 66(1): 83–96, indexed in Pubmed: 5009253.
8. Thambyrajah J, Townend JN. Homocysteine and atherothrombosis- 
-mechanisms for injury. Eur Heart J. 2000; 21(12): 967–974, doi: 
10.1053/euhj.1999.1914, indexed in Pubmed: 10901508.
9. Tofler GH, D’Agostino RB, Jacques PF, et al. Association be-
tween increased homocysteine levels and impaired fibrinolytic 
potential: potential mechanism for cardiovascular risk. Thromb 
Haemost. 2002; 88(5): 799–804, indexed in Pubmed: 12428097.
606 www.cardiologyjournal.org
Cardiology Journal 2021, Vol. 28, No. 4
10. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study 
of coronary heart disease incidence in relation to fasting total 
homocysteine, related genetic polymorphisms, and B vitamins: 
the Atherosclerosis Risk in Communities (ARIC) study. Circula-
tion. 1998; 98(3): 204–210, doi: 10.1161/01.cir.98.3.204, indexed 
in Pubmed: 9697819.
11. Ubbink JB, Fehily AM, Pickering J, et al. Homocysteine and 
ischaemic heart disease in the Caerphilly cohort. Atherosclero-
sis. 1998; 140(2): 349–356, doi: 10.1016/s0021-9150(98)00139-7, 
indexed in Pubmed: 9862278.
12. Myocardial infarction redefined: a consensus document of 
The Joint European Society of Cardiology/American College 
of Cardiology Committee for the redefinition of myocardial in-
farction. Eur Heart J. 2000; 21(18): 1502–1513, doi: 10.1053/
euhj.2000.2305, indexed in Pubmed: 10973764.
13. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA 
guidelines for the management of patients with acute myocar-
dial infarction. A report of the American College of Cardiology/ 
/American Heart Association Task Force on Practice Guidelines 
(Committee on Management of Acute Myocardial Infarction). 
J Am Coll Cardiol. 1999; 34: 890–911.
14. Ryan T, Anderson J, Antman E, et al. ACC/AHA guidelines for 
the management of patients with acute myocardial infarction. 
J Am Coll Cardiol. 1996; 28(5): 1328–1419, doi: 10.1016/s0735-
1097(96)00392-0.
15. Tang EW, Wong CK, Herbison P. Global Registry of Acute Coro-
nary Events (GRACE) hospital discharge risk score accurately 
predicts long-term mortality post acute coronary syndrome. Am 
Heart J. 2007; 153(1): 29–35, doi: 10.1016/j.ahj.2006.10.004, in-
dexed in Pubmed: 17174633.
16. Charlson ME, Pompei P, Ales KL, et al. A new method of clas-
sifying prognostic comorbidity in longitudinal studies: develop-
ment and validation. J Chronic Dis. 1987; 40(5): 373–383, doi: 
10.1016/0021-9681(87)90171-8, indexed in Pubmed: 3558716.
17. Xu X, Hardin J. Regression models for bivariate count outcomes. 
Stata J. 2018; 16(2): 301–315, doi: 10.1177/1536867x1601600203.
18. Royston P, Sauerbrei W. Multivariable Model-Building: A Prag-
matic Approach to Regression Analysis Based on Fractional Poly-
nomials for Modelling Continuous Variables. Wiley, Chichester, 
UK 2008.
19. McCully KS. Vascular pathology of homocysteinemia: implica-
tions for the pathogenesis of arteriosclerosis. Am J Pathol. 1969; 
56(1): 111–128, indexed in Pubmed: 5792556.
20. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for 
vascular disease: plasma levels in health, disease, and drug ther-
apy. J Lab Clin Med. 1989; 114(5): 473–501, indexed in Pubmed: 
2681479.
21. Berman RS, Martin W. Arterial endothelial barrier dysfunction: 
actions of homocysteine and the hypoxanthine-xanthine oxidase 
free radical generating system. Br J Pharmacol. 1993; 108(4): 
920–926, doi: 10.1111/j.1476-5381.1993.tb13487.x, indexed in 
Pubmed: 8485631.
22. Heinecke JW, Rosen H, Suzuki LA, et al. The role of sulfur-
containing amino acids in superoxide production and modifica-
tion of low density lipoprotein by arterial smooth muscle cells. 
J Biol Chem. 1987; 262(21): 10098–10103, indexed in Pubmed: 
3038867.
23. Naruszewicz M, Mirkiewicz E, Kłosiewicz-Latoszek L. 
Modification of low density lipoproteins from hypertrigly- 
ceridemic patients by macrophages in vitro and the effect of 
bezafibrate treatment. Atherosclerosis. 1989; 79(2-3): 261–265, 
doi: 10.1016/0021-9150(89)90133-0, indexed in Pubmed: 
2597235.
24. Parthasarathy S. Oxidation of low-density lipoprotein by thiol 
compounds leads to its recognition by the acetyl LDL receptor. 
Biochim Biophys Acta. 1987; 917(2): 337–340, doi: 10.1016/0005-
2760(87)90139-1, indexed in Pubmed: 3801507.
25. Dudman NP, Temple SE, Guo XW, et al. Homocysteine enhances 
neutrophil-endothelial interactions in both cultured human cells 
and rats In vivo. Circ Res. 1999; 84(4): 409–416, doi: 10.1161/01.
res.84.4.409, indexed in Pubmed: 10066675.
26. Speidl WS, Nikfardjam M, Niessner A, et al. Mild hyperhomo-
cysteinemia is associated with a decreased fibrinolytic activity in 
patients after ST-elevation myocardial infarction. Thromb Res. 
2007; 119(3): 331–336, doi: 10.1016/j.thromres.2006.02.011, in-
dexed in Pubmed: 16616324.
27. McDonald L, Bray C, Field C, et al. Homocystinuria, thrombosis, 
and the blood-platelets. Lancet. 1964; 1(7336): 745–746, doi: 
10.1016/s0140-6736(64)92852-1, indexed in Pubmed: 14107984.
28. Fan Y, Wang J, Zhang S, et al. Homocysteine enhances the predic-
tive value of the GRACE risk score in patients with ST-elevation 
myocardial infarction. Anatol J Cardiol. 2017; 18(3): 182–193, 
doi: 10.14744/AnatolJCardiol.2017.7798, indexed in Pubmed: 
28782750.
29. Acevedo M, Pearce GL, Jacobsen DW, et al. Serum homocysteine 
levels and mortality in outpatients with or without coronary 
artery disease: an observational study. Am J Med. 2003; 114(8): 
685–688, doi: 10.1016/s0002-9343(03)00123-2, indexed in Pub-
med: 12798457.
30. Boushey CJ, Beresford SA, Omenn GS, et al. A quantita-
tive assessment of plasma homocysteine as a risk factor for 
vascular disease. Probable benefits of increasing folic acid 
intakes. JAMA. 1995; 274(13): 1049–1057, doi: 10.1001/
jama.1995.03530130055028, indexed in Pubmed: 7563456.
31. Study of the Effectiveness of Additional Reductions in C, Homo-
cysteine Collaborative G, Armitage JM, Bowman L, Clarke RJ, 
Effects of homocysteine-lowering with folic acid plus vitamin 
B12 vs placebo on mortality and major morbidity in myocar-
dial infarction survivors: a randomized trial. JAMA. 2010; 303: 
2486–2494, doi: 10.1001/jama.2010.840, indexed in Pubmed: 
20571015.
32. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and 
B vitamins on risk of cardiovascular events and total mortality 
among women at high risk for cardiovascular disease: a rand-
omized trial. JAMA. 2008; 299(17): 2027–2036, doi: 10.1001/
jama.299.17.2027, indexed in Pubmed: 18460663.
33. Toole JF, Malinow MR, Chambless LE, et al. Lowering homo-
cysteine in patients with ischemic stroke to prevent recurrent 
stroke, myocardial infarction, and death: the Vitamin Interven-
tion for Stroke Prevention (VISP) randomized controlled trial. 
JAMA. 2004; 291(5): 565–575, doi: 10.1001/jama.291.5.565, in-
dexed in Pubmed: 14762035.
34. Hultdin J, Thøgersen AM, Jansson JH, et al. Elevated plasma 
homocysteine: cause or consequence of myocardial infarc-
tion? J Intern Med. 2004; 256(6): 491–498, doi: 10.1111/j.1365-
2796.2004.01415.x, indexed in Pubmed: 15554950.
35. Nevado JB, Imasa MS. Homocysteine predicts adverse clini-
cal outcomes in unstable angina and non-ST elevation myo-
cardial infarction: implications from the folate intervention in 
non-ST elevation myocardial infarction and unstable angina 
study. Coron Artery Dis. 2008; 19(3): 153–161, doi: 10.1097/
MCA.0b013e3282f52910, indexed in Pubmed: 18418231.
36. Ma Yi, Li Li, Geng XB, et al. Correlation between hyperhomo-
cysteinemia and outcomes of patients with acute myocardial 
infarction. Am J Ther. 2016; 23(6): e1464–e1468, doi: 10.1097/
MJT.0000000000000130, indexed in Pubmed: 25405897.
